Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts.
Merchant KM, Simuni T, Fedler J, Caspell-Garcia C, Brumm M, Nudelman KNH, Tengstrandt E, Hsieh F, Alcalay RN, Coffey C, Chahine L, Foroud T, Singleton A, Weintraub D, Hutten S, Sherer T, Mollenhauer B, Siderowf A, Tanner C, Marek K; the Parkinson’s Progression Markers Initiative. Merchant KM, et al. NPJ Parkinsons Dis. 2023 Feb 28;9(1):30. doi: 10.1038/s41531-023-00468-2. NPJ Parkinsons Dis. 2023. PMID: 36854767 Free PMC article.
A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.
Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P; Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research. Mollenhauer B, et al. Among authors: merchant km. Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Mov Disord. 2017. PMID: 28734051 Free PMC article. Review.
Finding useful biomarkers for Parkinson's disease.
Chen-Plotkin AS, Albin R, Alcalay R, Babcock D, Bajaj V, Bowman D, Buko A, Cedarbaum J, Chelsky D, Cookson MR, Dawson TM, Dewey R, Foroud T, Frasier M, German D, Gwinn K, Huang X, Kopil C, Kremer T, Lasch S, Marek K, Marto JA, Merchant K, Mollenhauer B, Naito A, Potashkin J, Reimer A, Rosenthal LS, Saunders-Pullman R, Scherzer CR, Sherer T, Singleton A, Sutherland M, Thiele I, van der Brug M, Van Keuren-Jensen K, Vaillancourt D, Walt D, West A, Zhang J. Chen-Plotkin AS, et al. Sci Transl Med. 2018 Aug 15;10(454):eaam6003. doi: 10.1126/scitranslmed.aam6003. Sci Transl Med. 2018. PMID: 30111645 Free PMC article. Review.
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group. Merchant KM, et al. J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471. J Parkinsons Dis. 2019. PMID: 30400107 Free PMC article.
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Frank S, Jennings D, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board. Prakash N, et al. Parkinsonism Relat Disord. 2019 May;62:201-209. doi: 10.1016/j.parkreldis.2018.12.025. Epub 2019 Jan 31. Parkinsonism Relat Disord. 2019. PMID: 30738748 Free PMC article.
An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, Lawrence-Henderson R, Levers N, Joshi N, Ma TC, Liong C, Narayan S, Alcalay RN, Hutten SJ, Baptista MAS, Merchant K. Padmanabhan S, et al. J Parkinsons Dis. 2020;10(2):623-629. doi: 10.3233/JPD-191786. J Parkinsons Dis. 2020. PMID: 32007961 Free PMC article.
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, Estrada AA, Fell MJ, Fiske BK, Fuji RN, Galatsis P, Henry AG, Hill S, Hirst W, Houle C, Kennedy ME, Liu X, Maddess ML, Markgraf C, Mei H, Meier WA, Needle E, Ploch S, Royer C, Rudolph K, Sharma AK, Stepan A, Steyn S, Trost C, Yin Z, Yu H, Wang X, Sherer TB. Baptista MAS, et al. Sci Transl Med. 2020 Apr 22;12(540):eaav0820. doi: 10.1126/scitranslmed.aav0820. Sci Transl Med. 2020. PMID: 32321864
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative. Alcalay RN, et al. Ann Clin Transl Neurol. 2020 Oct;7(10):1816-1830. doi: 10.1002/acn3.51164. Epub 2020 Sep 5. Ann Clin Transl Neurol. 2020. PMID: 32888397 Free PMC article.
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G; Parkinson Study Group NILO-PD Investigators and Collaborators. Simuni T, et al. JAMA Neurol. 2021 Mar 1;78(3):312-320. doi: 10.1001/jamaneurol.2020.4725. JAMA Neurol. 2021. PMID: 33315105 Free PMC article. Clinical Trial.
90 results